<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703140</url>
  </required_header>
  <id_info>
    <org_study_id>2020/09</org_study_id>
    <nct_id>NCT04703140</nct_id>
  </id_info>
  <brief_title>COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19</brief_title>
  <acronym>COVIDISC</acronym>
  <official_title>Evaluation of the Performance of COVIDISC Rapid Test for Diagnosis of SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Covid-19 pandemic requires a reliable diagnosis of patients in order to take care of them&#xD;
      in the best conditions and in the appropriate services. Moreover, the current diagnostic&#xD;
      reference is reverse transcription by polymerase chain reaction (RT-PCR) on a nasopharyngeal&#xD;
      sample taken by swab. This technique is expensive (54€) and its production time is several&#xD;
      hours.&#xD;
&#xD;
      Alternative methods are in progress, including, rapid diagnostic tests. The MEMS microfluids&#xD;
      and nanostructures (MMN) laboratory, in partnership with the Institut Chimie Biologie&#xD;
      Innovation (CBI) (Paris, 75005), have developed a portable test &quot;COVIDISC&quot;, low-cost (10 €),&#xD;
      fast (1 hour), including extraction, elution and amplification in solid medium isothermal,&#xD;
      reverse amplification loop mediated transcription (RT-LAMP).&#xD;
&#xD;
      The &quot;lab&quot; version has received an analytical validation on human nasopharyngeal samples with&#xD;
      performance comparable to classic RT-PCR (sensitivity of 7 copies per μl, specificity 100%).&#xD;
&#xD;
      The objective of this study is to validate the in vitro diagnostic medical device, COVIDISC,&#xD;
      with the standard nasopharyngeal RT-PCR test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All outpatients and hospitalized patients (intensive care unit, internal medicine service and&#xD;
      emergency service) will be proposed to participate to the study after assessment of&#xD;
      eligibility criteria by the investigator. The investigator will collect a written consent of&#xD;
      the patient or from the support person or a familiar if, the patient is not in condition to&#xD;
      consent. Patient's participation will be notified in his medical record.&#xD;
&#xD;
      After inclusion of patient, the nurse will collect general and clinical data and 2&#xD;
      nasopharyngeal swabs will be taken. One sample to test the prototype of the RT-LAMP and the&#xD;
      second one to carry out the classic RT-PCR. The results will be collected and compared in a&#xD;
      second step.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparaison of the performance of the diagnostic performance (sensitivity, sensibility) of RT-LAMP test using the RT-PCR test as a reference.</measure>
    <time_frame>Day 0</time_frame>
    <description>Calculate sensitivity, Specificity, Positive predictive value, Negative predictive value, Positive and negative likelihood report COVIDISC fast, antigenic test compared to RT-PCR Covid-19 reference test conducted in the laboratory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the diagnostic performances of RT-LAMP to clinical diagnosis.</measure>
    <time_frame>Day 0</time_frame>
    <description>The result of RT-LAMP test versus clinical evaluation defined by the clinical symptoms of the patients at the time of nasopharyngeal swab.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>nasopharyngeal swabs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One patient will have 2 nasopharyngeal for PCR and COVIDISC</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid Diagnostic Test vs PCR</intervention_name>
    <description>2 nasopharyngeal swabs taken for PCR and COVIDISC</description>
    <arm_group_label>nasopharyngeal swabs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing nasopharyngeal SARS CoV2 RT-PCR testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
&#xD;
          -  Having signed a written informed consent form,&#xD;
&#xD;
          -  Affiliation to the social security system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROSSI Benjamin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Robert Ballanger</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NGUYEN Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMC Ambroise Paré</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROSSI Benjamin, MD</last_name>
    <phone>(+33) 1 49 36 73 67</phone>
    <email>benjamin_rossi@hotmail.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

